Business :--  Biometric technologies

Listing    :--  NASDAQ Global Market

Proposed Symbol  :--  " CROS "  

Common stock offered by company

8,333,334 shares

Common stock offered by selling stockholders

3,500,000 shares

Total common stock to be outstanding immediately after this offering

28,694,610 shares

The underwriters have an option to purchase a maximum of 1,775,000 additional shares from company to cover over-allotments of shares.

Proceeds

Estimate net proceeds to company from this offering will be approximately US$114.2 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by company. A $1.00 increase (decrease) in the assumed initial public offering price of US$15.00 per share would increase (decrease) the net proceeds from this offering by approximately US$7.8 million, assuming that the number of shares offered by company remains the same.

Use of proceeds

• To pay in full the $4.4 million principal amount, along with accrued interest, outstanding under a term loan agreement

• Company pursue acquisitions of other businesses as part of its business strategy and may use a portion of the net proceeds to fund acquisitions, although it has no agreement with respect to any future acquisition.

Pending such uses, company may invest the net proceeds from this offering in short-term investments. 

Common stock to be outstanding be outstanding after this offering excludes:

• 3,192,805 shares of common stock reserved for issuance under new 2007 Omnibus Incentive Plan;

• 6,804,141 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2007;

• 1,377,466 shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2007.